Smith On Stocks
Contributor since: 2011
Company: SmithOnStocks.com
KaloBios: Martin Shkreli Arrested; This Could Be A Major Catalyst For Small Biotechnology Stocks
Discovery Laboratories: Results For Phase 2a Trial Are Quite Encouraging; Why Then Did The Stock Crash
What Astra Zeneca Is Acquiring With ZS Pharma
Northwest Biotherapeutics: Analysis Of A Coordinated Short Selling Attack Against The Stock
Comments On Data Presented By Northwest Biotherapeutics On DCVax Direct At ASCO
A Detailed Sales And Profit Model For Antares
Northwest Biotherapeutics: Analysis Of Promising New Data Was Just Presented On DCVax-L In Recurrent Glioblastoma Multiforme
Neuralstem: A Closer Look At Encouraging Phase 2 Results For NSI-566 Neural Stem Cells In Treating ALS (CUR, Buy, $2.36)
Neuralstem: Initial Take On Top Line Results Of Phase 2 ALS Trial Of NSI-566 Neural Stem Cells
ImmunoCellular Therapeutics: Is There An Investment Case To Be Made? (IMUC, No Opinion, $0.56)
The Potentially Key Role Of Northwest Biotherapeutics In The Emerging Immuno-Oncology Landscape
Immuno-Oncology Promises To Be The Next “Big Thing” In Biotechnology
Antares Pharmaceuticals: Highlights Of Presentation At JP Morgan Conference (ATRS, $2.36. Buy)
Notes From Neuralstem Presentation At Biotech Showcase Conference, January 13, 2015 (CUR, Buy, $3.09)
Delay In Quick Shot Testosterone Clinical Program Is Not A Major Setback For The Stock (ATRS, Buy, $2.53)
Notes From Linda Powers Presentation In San Francisco
Agenus: The Collaboration With Incyte Is Transformative And Creates Great Shareholder Value (AGEN, Buy, $4.99)
Repligen: Revenues For 2014 Are Above Expectations And Guidance For 2015 Is For Strong Growth (RGEN, Hold/ Buy, $23.84)
Derma Sciences: Sales Guidance For 2014 Is Lowered Again; 2015 Sales Guidance Is Given For The First Time (DSCI, Hold, $9.40)
Cytokinetics: Takeaways From January 5th Conference Call ($7.82, Buy)
Cytokinetics: With The Stock Up 63% In The Last Seven Trading Days, What Do We Do Now?
Cytokinetics: New Collaboration With Astellas On CK-2127107 Greatly Improves Investment Outlook
Neuralstem: Some Encouraging, But Very Early, Information On Chinese Ischemic Stroke Trial Using NSI-566 Stem Cells
Washington Post Calls For An Investigation Into Hedge Fund Trading And Adam Feuerstein's Blogging
Northwest Biotherapeutics: Washington Post Calls For Investigation Of Hedge Fund Stock Trading Practices
My Dialogue With Adam Feuerstein On Northwest Biotherapeutics
Discovery Laboratories: Surfaxin Launch Is Slow; Aerosurf Outlook Is Key To The Stock
ImmunoCellular: Thoughts On Management's Plan To Move ICT-107 Into Phase 3
Derma Sciences: Highlights Of The June 17th Analysts' Meeting
Northwest Biotherapeutics: The Perfect Storm May Be Brewing For Short Sellers
Northwest Biotherapeutics: The Investment Tide May Be Turning Positive
Northwest Biotherapeutics Releases Promising Early Results In DCVax Direct Phase 1 Trial